The global human papillomavirus vaccine market was valued at
approximately US$ 2.0 Bn in 2016 is anticipated to register compound
annual growth rate (CAGR) of over 5.0% from 2017 to 2025, according
to a new report published by Transparency Market Research (TMR)
titled “Human Papillomavirus Vaccine Market – Global Industry
Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.
The report suggests that rise in incidences of cervical cancer and
anal cancer is anticipated to increase demand for human
papillomavirus vaccine during the forecast period. Western Europe and
North America are likely to account for a dominant share of the
global human papillomavirus vaccine market due to the launch of new
vaccines by key players in these regions. Rising burden of human
papillomavirus infections in emerging economies such as China and
India is likely to boost the human papillomavirus vaccine market in
Asia Pacific. The market in the region is anticipated expand at a
CAGR of over 9.5% from 2017 to 2025.
Request Sample for more Comprehensive Analysis @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=37085
Increasing prevalence of various cancers caused by human
papillomavirus is anticipated to drive the market during the forecast
period. According to the Centers for Disease Control and Prevention
(CDC), human papillomavirus is the most common sexually transmitted
infections (STI) in the U.S. Over 60% of penile cancers, 70% of
vulvar and vaginal cancers, and 90% of anal and cervical cancers are
caused due to infection of human papillomavirus. CDC also states that
about 14 million people are infected by human papillomavirus every
year in the U.S. Increase in government initiatives to prevent
cervical cancer caused by human papillomavirus. According to Cancer
Council Australia, nearly all schools in Australia have chosen to
participate in the National Human Papillomavirus Vaccination Program.
More than 9 million doses of vaccines have been administered to girls
and young women in Australia. This initiation resulted in
approximately 90% decrease in genital warts among heterosexual women
and men under the age of 21 years and approximately 50% decrease in
high grade cervical abnormalities in Victorian girls under 18 years
of age.
The global human papillomavirus vaccine market has been categorized
based on valance, indication, distribution channel, and region. Based
on valence, the market has been bifurcated into quadrivalent and
nonavalent segment is projected to lead the market and is expected to
continue its dominance during the forecast period followed by
bivalent segment. Launch of new human papillomavirus vaccines and
increase in incidences of cervical cancer are likely to propel the
segment. In December 2014, Merck & Co., Inc. announced to have
received an approval from the U.S. Food and Drug Administration (FDA)
for Gardasil 9, a recombinant human papillomavirus 9-valent vaccine
for the use in girls and young women aged between 9 and 26. The
vaccine is used for the prevention of vaginal, vulvar, anal, and
cervical cancers caused by human papillomavirus. The vaccine was also
approved for use in boys between the ages of 9 and 15 for the
prevention of precancerous lesions, anal cancer, and genital warts.
Enquire for Discount @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=37085
In terms of indication type, the cervical cancer segment dominated
the market in 2016 and it is anticipated to continue its dominance
during the forecast period. Anal cancer was the second largest
segment in 2016 and is likely to continue its dominance from 2017 to
2025. In 2017, the American Society of Clinical Oncology (ASCO)
stated that nearly 12,820 women will be diagnosed with cervical
cancer in the U.S., and approximately 4,210 will succumb to the
disease. According to Cancer Research UK, approximately 3,126 new
cervical cancer cases were diagnosed in 2015. In terms of
distribution channel, government entities held dominant share of the
market. However, it is anticipated to lose market share during the
forecast period owing to public and private alliances such as GAVI
that are focused to vaccinating people in developing countries are
anticipated to gain market share due to increase in prevalence of
human papillomavirus infectious cancerous diseases in developing
countries.
Geographically, North America accounted for the largest share of
global human papillomavirus vaccine market in 2016. Increasing
recommendations by various associations for immunization practices in
the U.S. is attributed to increase market share of the region. Merck
& Co., Inc. announced to have received recommendations from the
U.S. Advisory Committee on Immunization Practices (ACIP), and CDC
voted to include Gardasil 9, a recombinant human papillomavirus
9-valent vaccine to the routine recommendations for vaccination of 11
and 12 years old children. Vaccination was also recommended for
females aged 13 to 26 and males aged 13 to 21 who have not been
vaccinated previously or have not completed the three-dose series.
The market in Asia Pacific is projected to gain share during the
forecast period and is likely to be key revenue generator in the next
few years. In July 2017, GlaxoSmithKline plc received approval for
Cervarix, a product by China FDA. This is anticipated to drive the
human papillomavirus vaccine market in the region. Government
initiatives to reduce infectious diseases caused by human
papillomavirus are likely to drive the market in Middle East &
Africa and Latin America.
Key players operating in the human papillomavirus vaccine market and
profiled in the report include Merck & Co., Inc., GlaxoSmithKline
plc, Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute
of India Pvt. Ltd. These players adopted inorganic and organic growth
strategies to increase their vaccine offerings, strengthen their
reach across the globe, garner market share, and increase customer
base.
Request TOC of the Report for Complete Review @
https://www.transparencymarketresearch.com/report-toc/37085
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment